- Home
- AUTL vs NEWT Comparison
AUTL vs NEWT Comparison
Compare AUTL & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.67
Company Overview
Basic Information| Metric | AUTL | NEWT |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 395.5M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUTL | NEWT |
|---|---|---|
| Price | $1.67 | $12.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | $8.50 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.4M | 163.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.29% |
| EPS Growth | ★ 28.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $669.62 | N/A |
| Revenue Next Year | $79.78 | $12.45 |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $9.12 |
| 52 Week High | $2.70 | $14.91 |
Technical Indicators
Market Signals| Indicator | AUTL | NEWT |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 43.58 |
| Support Level | $1.27 | $11.72 |
| Resistance Level | $1.74 | $12.41 |
| Average True Range (ATR) | 0.12 | 0.46 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 37.63 | 49.61 |
Price Performance
Historical Comparison AUTL
NEWT
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.